Skip to main content

Advertisement

Table 1 Characteristics of selected studies (n = 489) by funding: industry or non-industry

From: Public availability of results of observational studies evaluating an intervention registered at ClinicalTrials.gov

Characteristics Industry funded (totally or partially) (n = 334) Non-industry funded (n = 155) Total (n = 489)
Registration Before the start date of the study 69 (20.7) 43 (27.7) 112 (22.9)
  Between the start date of the study and study primary completion date 174 (52.1) 58 (37.4) 232 (47.4)
  After the study primary completion date 91 (27.2) 54 (34.8) 145 (29.7)
Medical field Cardiovascular 51 (15.3) 27 (17.4) 78 (16.0)
  Endocrinology 61 (18.3) 4 (2.6) 65 (13.3)
  Infectious diseases 46 (13.8) 16 (10.3) 62 (12.7)
  Urology/gynecology 30 (9.0) 13 (8.4) 43 (8.8)
  Rheumatology 23 (6.9) 2 (1.3) 25 (5.1)
  Bronchopulmonary 20 (6.0) 9 (5.8) 29 (5.9)
  Neurology 18 (5.4) 6 (3.9) 24 (4.9)
  Oncology 12 (3.6) 10 (6.5) 22 (4.9)
  Gastroenterology 11 (3.3) 19 (12.3) 30 (6.1)
  Ophthalmology 10 (3.0) 9 (5.8) 19 (3.9)
  Psychiatry 10 (3.0) 2 (1.3) 12 (2.5)
  Other 42 (12.6) 38 (24.5) 80 (16.4)
Location Africa/Asia/South America 114 (34.1) 42 (27.1) 156 (31.9)
  Europe/Australia/North America 220 (65.9) 113 (72.9) 333 (68.1)
Intervention Drug 278 (83.2) 52 (33.5) 330 (67.5)
  Device 43 (12.9) 45 (29.0) 88 (18.0)
  Procedure/surgery 9 (2.7) 54 (34.8) 63 (12.9)
  Other 4 (1.2) 4 (2.6) 8 (1.6)
Sample size ≤100 68 (20.4) 94 (60.6) 162 (33.1)
  100–500 95 (28.4) 40 (25.8) 135 (27.6)
  >500 171 (51.2) 21 (13.5) 192 (39.3)
Study objective Safety or both safety and efficacy 279 (83.5) 72 (46.5) 351 (71.8)
Efficacy 55 (16.5) 83 (53.5) 138 (28.2)
  1. Data are presented as number (%)